PEOPLE - Stentys makes appointment:
This article was originally published in Clinica
Executive Summary
French drug-eluting stent developer Stentys has appointed Hikmat Hojeibane as chief technology officer. Mr Hojeibane, who has more than 20 years' experience in the industry, joins the Paris-based firm from Johnson & Johnson. There, he held several technical leadership positions, including director of technology assessments (Ethicon), director of R&D (Cardiovations) and engineering fellow (Cordis). He has also worked for CR Bard and B Braun Medical.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.